Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Comment by Smokey1958on Aug 18, 2024 12:12pm
143 Views
Post# 36184926

RE:RE:Apparently the codes have been approved

RE:RE:Apparently the codes have been approvedI should have stated profit generating (instead of revenue generating) as the margins on these devices tends to be high. Most sources indicate anywhere between 20% to 30%. For THRM to move forward in the next 6 months to a year and establish even $2 million in sales with gross profits of $400 thousand to $600 thousand could reduce the requirement to ever significantly dilute the outstanding share count again. More importantly it would eliminate any discussion in the need for a R/S ....which has reared it's ugly head at times.

Let's hope Monday is the start of a significant change in fortune for the latter part of 2024!!!
<< Previous
Bullboard Posts
Next >>